Agios Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Agios Pharmaceuticals wird ein jährliches Gewinn- und Umsatzwachstum von 14.6% bzw. 53.2% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 18.2% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -23.3% betragen.

Wichtige Informationen

8.2%

Wachstumsrate der Gewinne

11.1%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.4%
Wachstumsrate der Einnahmen	53.1%
Zukünftige Eigenkapitalrendite	-23.3%
Analystenabdeckung	Good
Zuletzt aktualisiert	26 Sep 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

Aug 04

Recent updates

We're Not Very Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Rate

Sep 26

Agios' Mitapivat: A Potential Blockbuster In Thalassemia Treatment

Aug 27

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

Aug 04

Agios Pharmaceuticals: Potential Acquisition Target, Upcoming FDA Approvals, Promising Pipeline

Jun 12

Companies Like Agios Pharmaceuticals (NASDAQ:AGIO) Are In A Position To Invest In Growth

Jun 02

Bearish: Analysts Just Cut Their Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Revenue and EPS estimates

Feb 17

Here's Why We're Not Too Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Situation

Jan 16

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Analysts Just Trimmed Their Revenue Forecasts By 50%

Nov 09

Here's Why We're Not Too Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Situation

Sep 26

Are Investors Undervaluing Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) By 48%?

May 08

We're Hopeful That Agios Pharmaceuticals (NASDAQ:AGIO) Will Use Its Cash Wisely

Feb 06

Agios Pharmaceuticals (NASDAQ:AGIO) Is In A Good Position To Deliver On Growth Plans

Oct 18

Agios Pyrukynd for rare blood disorder gets EMA panel backing for approval in EU

Sep 16

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Analysts Just Trimmed Their Revenue Forecasts By 46%

Dec 21

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:AGIO - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	183	-324	-259	N/A	7
12/31/2025	108	-363	-240	-323	8
12/31/2024	38	211	-308	-309	7
6/30/2024	31	-365	-325	-307	N/A
3/31/2024	29	-353	-319	-301	N/A
12/31/2023	27	-352	-315	-296	N/A
9/30/2023	24	-220	-308	-290	N/A
6/30/2023	20	-210	-300	-299	N/A
3/31/2023	19	-218	-309	-307	N/A
12/31/2022	14	-232	-314	-309	N/A
9/30/2022	10	-367	-337	-327	N/A
6/30/2022	6	-369	-350	-341	N/A
3/31/2022	1	-360	-392	-384	N/A
12/31/2021	N/A	-357	-413	-407	N/A
9/30/2021	N/A	-342	-374	-373	N/A
6/30/2021	N/A	-337	-363	-356	N/A
3/31/2021	N/A	-336	-317	-306	N/A
12/31/2020	N/A	-329	-305	-291	N/A
9/30/2020	35	-347	-355	-335	N/A
6/30/2020	61	-374	-370	-352	N/A
3/31/2020	88	-402	-387	-373	N/A
12/31/2019	N/A	-301	-383	-371	N/A
9/30/2019	112	-401	-358	-351	N/A
6/30/2019	102	-389	-337	-329	N/A
3/31/2019	116	-348	-316	-309	N/A
12/31/2018	94	-346	-311	-304	N/A
9/30/2018	74	-343	-312	-305	N/A
6/30/2018	70	-325	-325	-319	N/A
3/31/2018	41	-339	N/A	-310	N/A
12/31/2017	43	-315	N/A	-285	N/A
9/30/2017	56	-283	N/A	-262	N/A
6/30/2017	53	-269	N/A	-233	N/A
3/31/2017	49	-241	N/A	-17	N/A
12/31/2016	70	-198	N/A	39	N/A
9/30/2016	53	-183	N/A	59	N/A
6/30/2016	50	-160	N/A	83	N/A
3/31/2016	56	-136	N/A	-70	N/A
12/31/2015	59	-118	N/A	-77	N/A
9/30/2015	68	-104	N/A	-54	N/A
6/30/2015	96	-60	N/A	-53	N/A
3/31/2015	91	-46	N/A	-58	N/A
12/31/2014	65	-54	N/A	-59	N/A
9/30/2014	57	-39	N/A	-65	N/A
6/30/2014	30	-55	N/A	-57	N/A
3/31/2014	28	-47	N/A	-71	N/A
12/31/2013	26	-44	N/A	-56	N/A
9/30/2013	25	-49	N/A	-54	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: AGIO wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: AGIO wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: AGIO wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: AGIODie Einnahmen des Unternehmens (49.4% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: AGIODie Einnahmen des Unternehmens (49.4% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: AGIO wird voraussichtlich in 3 Jahren unrentabel sein.

Agios Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

Forecast to breakeven in 2024

Consensus EPS estimates upgraded to US$3.16 loss

Price target increased by 13% to US$46.00

Consensus revenue estimates decrease by 33%, EPS upgraded

Consensus revenue estimates increase by 46%

Recent updates

We're Not Very Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Rate

Agios' Mitapivat: A Potential Blockbuster In Thalassemia Treatment

CEO & Director notifies of intention to sell stock

Agios to Receive $1.1 Billion in Milestone Payments Following FDA Approval of Vorasidenib

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

New major risk - Revenue and earnings growth

Agios Pharmaceuticals, Inc. Announces Results from Phase 3 ACTIVATE-KidsT Study of Mitapivat in Children with PK Deficiency Who Are Regularly Transfused

New minor risk - Profitability

Agios Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Agios Pharmaceuticals, Inc. Presents Positive Results from Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia in Plenary Session at the European Hematology Association 2024 Hybrid Congress

Forecast to breakeven in 2024

Agios Pharmaceuticals: Potential Acquisition Target, Upcoming FDA Approvals, Promising Pipeline

CEO & Director notifies of intention to sell stock

New minor risk - Share price stability

Agios Pharmaceuticals, Inc. Announces Phase 3 Energize-T Study of Mitapivat Met Primary Endpoint and All Key Secondary Endpoints in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia

Companies Like Agios Pharmaceuticals (NASDAQ:AGIO) Are In A Position To Invest In Growth

Consensus EPS estimates upgraded to US$3.16 loss

Price target increased by 13% to US$46.00

Consensus revenue estimates decrease by 33%, EPS upgraded

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

New minor risk - Shareholder dilution

Agios Pharmaceuticals, Inc., Annual General Meeting, Jun 20, 2024

Chair of the Board of Directors exercised options and sold US$215k worth of stock

Independent Director notifies of intention to sell stock

Consensus revenue estimates increase by 46%

Full year 2023 earnings: EPS and revenues miss analyst expectations

Bearish: Analysts Just Cut Their Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Revenue and EPS estimates

Consensus revenue estimates fall by 43%

Agios Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 15, 2024

Chair of the Board of Directors exercised options and sold US$232k worth of stock

Here's Why We're Not Too Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Situation

CEO & Director exercised options and sold US$277k worth of stock

Agios Pharmaceuticals, Inc. Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio

Agios Pharmaceuticals, Inc. Presents Positive Results from Phase 2 Portion of the Rise Up Pivotal Study in Sickle Cell Disease at 65Th ASH Annual Meeting and Exposition

Agios Pharmaceuticals, Inc. Announces Clinical Proof-Of-Concept in Phase 2A Trial of AG-946 for the Treatment of Anemia in Lower-Risk Myelodysplastic Syndromes

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Analysts Just Trimmed Their Revenue Forecasts By 50%

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Agios Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Here's Why We're Not Too Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Situation

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Agios Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 03, 2023

CEO & Director exercised options and sold US$325k worth of stock

Agios Pharmaceuticals, Inc. Announces Board Changes

Are Investors Undervaluing Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) By 48%?

Director exercised options and sold US$226k worth of stock

Director exercised options and sold US$262k worth of stock

Director exercised options and sold US$269k worth of stock

Director exercised options and sold US$326k worth of stock

Chair of the Board of Directors exercised options and sold US$105k worth of stock

We're Hopeful That Agios Pharmaceuticals (NASDAQ:AGIO) Will Use Its Cash Wisely

Director exercised options and sold US$406k worth of stock

Director notifies of intention to sell stock

Insider exercised options and sold US$79k worth of stock

Agios Pharmaceuticals, Inc. Presents Updated PYRUKYND® (mitapivat) Long-term Extension Data Demonstrating Sustained Clinical Benefits in Adults with Pyruvate Kinase (PK) Deficiency at 64th ASH Annual Meeting and Exposition

Agios Pharmaceuticals, Inc. Appoints Tsveta Milanova as Chief Commercial Officer, Effective Jan. 3, 2023

Price target decreased to US$36.20

Price target increased to US$39.20

Agios Pharmaceutical's PYRUKYND® Approves in the EU for the Treatment of Pyruvate Kinase (PK) Deficiency in Adult Patients

Consensus forecasts updated

Agios Pharmaceuticals (NASDAQ:AGIO) Is In A Good Position To Deliver On Growth Plans

Agios Pharmaceuticals, Inc. Appoints Cecilia Jones as Chief Financial Officer, Effective September 26, 2022

Agios Pharmaceuticals, Inc. Receives Positive Chmp Opinion for Pyrukynd® (Mitapivat) for the Treatment of Pyruvate Kinase (Pk) Deficiency in Adult Patients

Agios Pyrukynd for rare blood disorder gets EMA panel backing for approval in EU

Agios Pharmaceuticals, Inc. Announces Resignation of Jonathan Biller as Chief Financial Officer, Effective September 16, 2022

Agios adds more than 13% after Novo deal to acquire rival Forma

Agios Pharmaceuticals, Inc. Appoints Rahul Ballal and Cynthia Smith to Board of Directors

Agios Pharmaceuticals, Inc. Announces Publication of Phase 2 Data in The Lancet Demonstrating Safety and Efficacy of PYRUKYND® (mitapivat) in Non-transfusion-dependent a- and ß-Thalassemia

Insufficient new directors